{
    "nct_id": "NCT05322473",
    "official_title": "Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa",
    "inclusion_criteria": "1. Participant is ≥18 years of age;\n2. Participant has been diagnosed with hidradenitis suppurativa as determined by the investigator and has a history of signs and symptoms of hidradenitis suppurativa dating back at least 6 months prior to the Screening Visit;\n3. Participant has a total abscess and/or inflammatory nodule (AN) count of ≥5;\n4. Participant has hidradenitis suppurativa lesions present in ≥2 distinct anatomical areas, at least one of which must contain single or multiple fistulas (i.e., be Hurley Stage II or III);\n5. Participant had an inadequate response to appropriate systemic antibiotics for treatment of hidradenitis suppurativa (or demonstrated intolerance to, or had a contraindication to, systemic antibiotics for treatment of their HS), in the investigator's opinion;\n6. Participant must be, in the opinion of the investigator, at both the Screening Visit and study treatment initiation, a suitable candidate for treatment with adalimumab per approved local product information.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participants with known hypersensitivity to sonelokimab or any of its excipients;\n2. Participants with known hypersensitivity to adalimumab or any of its excipients;\n3. Participant has a draining fistula count of ≥20 at the Screening Visit;\n4. Participant has any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of hidradenitis suppurativa;\n5. Prior exposure to more than 2 biologic response modifiers;\n6. Participant has a diagnosis of ulcerative colitis or Crohn's disease.",
    "miscellaneous_criteria": ""
}